Advertisement

Antiepileptic drug therapy in the elderly: a clinical pharmacological review

  • Upinder Kaur
  • Indal Chauhan
  • Indrajeet Singh Gambhir
  • Sankha Shubhra ChakrabartiEmail author
Review article

Abstract

Seizure disorder is the third most common neurological disorder in the elderly after stroke and dementia. With the increasing geriatric population, the situation of clinicians seeing more and more elderly epilepsy patients is very likely. Not only is the diagnosis of epilepsy tedious in the elderly, its management raises many challenging issues for the treating physicians. Altered physiology, age-related decline in organ function, and plasma protein binding and altered pharmacodynamics make the elderly patients with seizure disorder a difficult group to treat. This is further complicated by the presence of comorbidities and polypharmacy which increase the chances of drug interactions. The adverse effects that might be tolerated well in younger populations may be disastrous for the aged. Although the newer antiepileptic drugs are found to have a favorable safety profile, there is relative scarcity of randomized-controlled trials involving older and newer antiepileptics in the geriatric population. This review tries to compile the available literature on management of epilepsy in the elderly population including evidence of safety and efficacy of newer and older antiepileptics with special reference to the ‘geriatric giants’. It also deals with the interactions between antiepileptic medications and other commonly prescribed drugs in the elderly such as anti-hypertensives and antiischemic agents. The recommended guidelines of various international bodies are also analyzed from the perspective of elderly with seizure disorder.

Keywords

Seizures Elderly Antiepileptic drugs (AEDs) Pharmacology Safety Geriatric giants 

Notes

Compliance with ethical standards

Conflict of interest

Dr. Chakrabarti received honoraria from Novartis and Intas Pharmaceuticals. None of the other authors report any conflict of interest.

Informed consent/ethical approval

Not applicable.

Supplementary material

13760_2019_1132_MOESM1_ESM.docx (13 kb)
Supplementary material 1 (DOCX 13 kb)
13760_2019_1132_MOESM2_ESM.docx (16 kb)
Supplementary material 2 (DOCX 15 kb)
13760_2019_1132_MOESM3_ESM.docx (14 kb)
Supplementary material 3 (DOCX 14 kb)

References

  1. 1.
    Chen LA, Cheng SJ, Jou SB (2012) Epilepsy in the elderly. Int J Gerontol 6(2):63–67Google Scholar
  2. 2.
    Acharya JN, Acharya VJ (2014) Epilepsy in the elderly: special considerations and challenges. Ann Indian Acad Neurol 17(Suppl 1):S18–S26Google Scholar
  3. 3.
    Pugh MJV, Van Cott AC, Cramer JA, Knoefel JE, Amuan ME, Tabares J et al (2008) Trends in antiepileptic drug prescribing for older patients with new-onset epilepsy: 2000–2004. Neurology 70(22 Pt 2):2171–2178Google Scholar
  4. 4.
    de Assis TR, Nascimento OJM, Costa G, Bacellar A (2014) Antiepileptic drugs patterns in elderly inpatients in a Brazilian tertiary center, Salvador, Brazil TT—uso de drogas antiepilépticas em idosos internados em centro terciário, Salvador, Brasil. Arq Neuropsiquiatr 72(11):874–880Google Scholar
  5. 5.
    Bruun E, Virta LJ, Kälviäinen R, Keränen T (2015) Choice of the first anti-epileptic drug in elderly patients with newly diagnosed epilepsy: a Finnish retrospective study. Seizure 31:27–32Google Scholar
  6. 6.
    Higashida K, Tanaka T, Yamagami H, Tomari S, Fukuma K, Okuno Y et al (2018) A nationwide multi-center questionnaire survey on the management and treatment of post-stroke seizure and epilepsy in Japan. Rinsho Shinkeigaku 58(4):217–222Google Scholar
  7. 7.
    Bathena SPR, Leppik IE, Kanner AM, Birnbaum AK (2017) Antiseizure, antidepressant, and antipsychotic medication prescribing in elderly nursing home residents. Epilepsy Behav 69:116–120Google Scholar
  8. 8.
    Theitler J, Brik A, Shaniv D, Berkovitch M, Gandelman-Marton R (2017) Antiepileptic drug treatment in community-dwelling older patients with epilepsy: a retrospective observational study of old- versus new-generation antiepileptic drugs. Drugs Aging 34(6):479–487Google Scholar
  9. 9.
    Huber DP, Griener R, Trinka E (2013) Antiepileptic drug use in Austrian nursing home residents. Seizure 22(1):24–27Google Scholar
  10. 10.
    Zhuo C, Jiang R, Li G, Shao M, Chen C, Chen G et al (2017) Efficacy and tolerability of second and third generation anti-epileptic drugs in refractory epilepsy: a network meta-analysis. Sci Rep 7(1):1–12Google Scholar
  11. 11.
    Pohlmann-Eden B, Marson AG, Noack-Rink M, Ramirez F, Tofighy A, Werhahn KJ et al (2016) Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study. BMC Neurol 16(1):149Google Scholar
  12. 12.
    Arif H, Buchsbaum R, Pierro J, Whalen M, Sims J, Resor SR Jr et al (2010) Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. Arch Neurol 67(4):408–415Google Scholar
  13. 13.
    Werhahn KJ, Trinka E, Dobesberger J, Unterberger I, Baum P, Deckert-Schmitz M et al (2015) A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia 56(3):450–459Google Scholar
  14. 14.
    Werhahn KJ, Klimpe S, Balkaya S, Trinka E, Krämer G (2011) The safety and efficacy of add-on levetiracetam in elderly patients with focal epilepsy: a one-year observational study. Seizure 20(4):305–311Google Scholar
  15. 15.
    Rowan AJ, Ramsay RE, Collins JF, Pryor F, Boardman KD, Uthman BM et al (2005) New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 64(11):1868–1873Google Scholar
  16. 16.
    Rambeck B, Wolf P (1993) Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 25(6):433–443Google Scholar
  17. 17.
    Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P (2010) A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 49(10):661–669Google Scholar
  18. 18.
    Bialer M, Doose DR, Murthy B, Curtin C, Wang S-S, Twyman RE et al (2004) Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 43(12):763–780Google Scholar
  19. 19.
    Patsalos PN (2004) Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 43(11):707–724Google Scholar
  20. 20.
    Barcs G, Walker EB, Elger CE, Scaramelli A, Stefan H, Sturm Y et al (2000) Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 41(12):1597–1607Google Scholar
  21. 21.
    May TW, Korn-Merker E, Rambeck B (2003) Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 42(12):1023–1042Google Scholar
  22. 22.
    Johannessen SI, Landmark CJ (2010) Antiepileptic drug interactions—principles and clinical implications. Curr Neuropharmacol 8(3):254–267Google Scholar
  23. 23.
    Theis JGW, Sidhu J, Palmer J, Job S, Bullman J, Ascher J (2005) Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine. Neuropsychopharmacology 30(12):2269–2274Google Scholar
  24. 24.
    Bourgeois BF (1996) Drug interaction profile of topiramate. Epilepsia 37(Suppl 2):S14–S17Google Scholar
  25. 25.
    Johannessen Landmark C, Patsalos PN (2010) Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother 10(1):119–140Google Scholar
  26. 26.
    Heiskanen T, Kalso E (2012) Non-analgesic effects of opioids: interactions between opioids and other drugs. Curr Pharm Des 18(37):6079–6089Google Scholar
  27. 27.
    Ruiz-Giménez J, Sánchez-Alvarez JC, Cañadillas-Hidalgo F, Serrano-Castro PJ, Andalusian Epilepsy Society (2010) Antiepileptic treatment in patients with epilepsy and other comorbidities. Seizure 19(7):375–382Google Scholar
  28. 28.
    Jankovic SM, Dostic M (2012) Choice of antiepileptic drugs for the elderly: possible drug interactions and adverse effects. Expert Opin Drug Metab Toxicol 8(1):81–91Google Scholar
  29. 29.
    Bialer M, Soares-da-Silva P (2012) Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia 53(6):935–946Google Scholar
  30. 30.
    Leppik IE (2004) Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 13(Suppl 1):S5–S9 (discussion S10) Google Scholar
  31. 31.
    Flesch G (2004) Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Investig 24(4):185–203Google Scholar
  32. 32.
    Sills G, Brodie M (2007) Pharmacokinetics and drug interactions with zonisamide. Epilepsia 48(3):435–441Google Scholar
  33. 33.
    Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R et al (2013) Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 54(3):551–563Google Scholar
  34. 34.
  35. 35.
    Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF et al (2018) Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy. Neurology 91(2):74–81Google Scholar
  36. 36.
    Eddy CM, Rickards HE, Cavanna AE (2011) The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord 4(6):385–407Google Scholar
  37. 37.
    Fritz N, Glogau S, Hoffmann J, Rademacher M, Elger CE, Helmstaedter C (2005) Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 6(3):373–381Google Scholar
  38. 38.
    Lippa CF, Rosso A, Hepler M, Jenssen S, Pillai J, Irwin D (2010) Levetiracetam: a practical option for seizure management in elderly patients with cognitive impairment. Am J Alzheimers Dis Other Demen 25(2):149–154Google Scholar
  39. 39.
    Ishizue N, Niwano S, Saito M, Fukaya H, Nakamura H, Igarashi T et al (2016) Polytherapy with sodium channel-blocking antiepileptic drugs is associated with arrhythmogenic ST-T abnormality in patients with epilepsy. Seizure 40:81–87Google Scholar
  40. 40.
    Guldiken B, Rémi J, Noachtar S (2016) Cardiovascular adverse effects of phenytoin. J Neurol 263(5):861–870Google Scholar
  41. 41.
    Saetre E, Abdelnoor M, Amlie JP, Tossebro M, Perucca E, Taubøll E et al (2009) Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine. Epilepsia 50(8):1841–1849Google Scholar
  42. 42.
    Can İ, Tholakanahalli V (2016) Carbamazepine-induced atrioventricular block in an elderly woman. Turk Kardiyol Dern Ars 44(1):68–70Google Scholar
  43. 43.
    Svalheim S, Luef G, Rauchenzauner M, Mørkrid L, Gjerstad L, Taubøll E (2010) Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine. Acta Neurol Scand Suppl 190:30–33Google Scholar
  44. 44.
    Kim DW, Lee S-Y, Shon Y-M, Kim JH (2013) Effects of new antiepileptic drugs on circulatory markers for vascular risk in patients with newly diagnosed epilepsy. Epilepsia 54(10):e146–e149Google Scholar
  45. 45.
    Mintzer S, Skidmore CT, Abidin CJ, Morales MC, Chervoneva I, Capuzzi DM et al (2009) Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol 65(4):448–456Google Scholar
  46. 46.
    Ley M, Principe A, Jiménez-Conde J, Rocamora R (2015) Assessing long-term effects of eslicarbazepine acetate on lipid metabolism profile, sodium values and liver function tests. Epilepsy Res 115:147–152Google Scholar
  47. 47.
    Katsiki N, Mikhailidis DP, Nair DR (2014) The effects of antiepileptic drugs on vascular risk factors: a narrative review. Seizure 23(9):677–684Google Scholar
  48. 48.
    Petty SJ, O’Brien TJ, Wark JD (2007) Anti-epileptic medication and bone health. Osteoporos Int 18(2):129–142Google Scholar
  49. 49.
    Jetté N, Lix LM, Metge CJ, Prior HJ, McChesney J, Leslie WD (2011) Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis. Arch Neurol 68(1):107–112Google Scholar
  50. 50.
    Mikati MA, Dib L, Yamout B, Sawaya R, Rahi AC, Fuleihan GEH (2006) Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. Neurology 67(11):2005–2014Google Scholar
  51. 51.
    Berghuis B, de Haan G-J, van den Broek MPH, Sander JW, Lindhout D, Koeleman BPC (2016) Epidemiology, pathophysiology and putative genetic basis of carbamazepine- and oxcarbazepine-induced hyponatremia. Eur J Neurol 23(9):1393–1399Google Scholar
  52. 52.
    Kibar S, Demir S, Sezer N, Köseoğlu BF, Dalyan Aras M, Kesikburun B (2015) Gabapentin-induced urinary incontinence: a rare side effect in patients with neuropathic pain. Case Rep Neurol Med 2015:1–3Google Scholar
  53. 53.
    Jafferany M, Shireen F, Ibrahim A (2010) Lamotrigine-induced vaginitis and dysuria in an adult woman with bipolar depression. Prim Care Companion J Clin Psychiatry 12:3Google Scholar
  54. 54.
    Malik AM, Usmani A (2013) Day time urinary incontinence due to valproate in a patient with idiopathic generalized tonic clonic seizures. J Case Rep 3(1):53–55Google Scholar
  55. 55.
    Gandhi S, McArthur E, Mamdani MM, Hackam DG, McLachlan RS, Weir MA et al (2016) Antiepileptic drugs and hyponatremia in older adults: two population-based cohort studies. Epilepsia 57(12):2067–2079Google Scholar
  56. 56.
    Berghuis B, van der Palen J, de Haan G-J, Lindhout D, Koeleman BPC, Sander JW et al (2017) Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy. Epilepsia 58(7):1227–1233Google Scholar
  57. 57.
    Nasrallah K, Silver B (2005) Hyponatremia associated with repeated use of levetiracetam. Epilepsia 46(6):972–973Google Scholar
  58. 58.
    Schoenberg MR, Rum RS, Osborn KE, Werz MA (2017) A randomized, double-blind, placebo-controlled crossover study of the effects of levetiracetam on cognition, mood, and balance in healthy older adults. Epilepsia 58(9):1566–1574Google Scholar
  59. 59.
    Mazza M, Martini A, Scoppetta M, Mazza S (2008) Effect of levetiracetam on depression and anxiety in adult epileptic patients. Prog Neuropsychopharmacol Biol Psychiatry 32(2):539–543Google Scholar
  60. 60.
    Pugh MJV, Copeland LA, Zeber JE, Wang C-P, Amuan ME, Mortensen EM et al (2012) Antiepileptic drug monotherapy exposure and suicide-related behavior in older veterans. J Am Geriatr Soc 60(11):2042–2047Google Scholar
  61. 61.
    Kalinin VV (2007) Suicidality and antiepileptic drugs: is there a link? Drug Saf 30(2):123–142Google Scholar
  62. 62.
    Pinheiro D (2008) Anticonvulsant mood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD). Encephale 34(4):409–415Google Scholar
  63. 63.
    Sommer OH, Aga O, Cvancarova M, Olsen IC, Selbaek G, Engedal K (2009) Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia. Dement Geriatr Cogn Disord 27(2):155–163Google Scholar
  64. 64.
    Gilad R (2012) Management of seizures following a stroke: what are the options? Drugs Aging 29(7):533–538Google Scholar
  65. 65.
    Goldstein LB (1995) Common drugs may influence motor recovery after stroke. The Sygen In Acute Stroke Study Investigators. Neurology 45(5):865–871Google Scholar
  66. 66.
    Verrotti A, Manco R, Matricardi S, Franzoni E, Chiarelli F (2007) Antiepileptic drugs and visual function. Pediatr Neurol 36(6):353–360Google Scholar
  67. 67.
    Stefan H, Bernatik J, Knorr J (1999) Visual field defects due to antiepileptic drugs. Nervenarzt 70(6):552–555Google Scholar
  68. 68.
    Hmouda H, Ben Salem C, Grira M, Slim R, Bouraoui K (2007) Carbamazepine-induced urinary retention. Br J Clin Pharmacol 64(6):833–834Google Scholar
  69. 69.
    Bar S, Feller N, Savir H (1983) Presenile cataracts in phenytoin-treated epileptic patients. Arch Ophthalmol (Chicago, Ill 1960) 101(3):422–425Google Scholar
  70. 70.
    Villanueva V, Giráldez BG, Toledo M, De Haan GJ, Cumbo E, Gambardella A et al (2018) Lacosamide monotherapy in clinical practice: a retrospective chart review. Acta Neurol Scand 138(3):186–194Google Scholar
  71. 71.
    Rohracher A, Zimmermann G, Villanueva V, Garamendi I, Sander JW, Wehner T et al (2018) Perampanel in routine clinical use across Europe: pooled, multicenter, observational data. Epilepsia 59(9):1727–1739Google Scholar
  72. 72.
    Leppik IE, Wechsler RT, Williams B, Yang H, Zhou S, Laurenza A (2015) Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials. Epilepsy Res 110:216–220Google Scholar
  73. 73.
    Brodie MJ, Whitesides J, Schiemann J, D’Souza J, Johnson ME (2016) Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: a pooled analysis from three phase III studies. Epilepsy Res 127:114–118Google Scholar

Copyright information

© Belgian Neurological Society 2019

Authors and Affiliations

  1. 1.Department of Pharmacology, Institute of Medical SciencesBanaras Hindu UniversityVaranasiIndia
  2. 2.Department of Geriatric Medicine, Institute of Medical SciencesBanaras Hindu UniversityVaranasiIndia

Personalised recommendations